liver
| 3 min read
Sagimet’s denifanstat delivered significant improvements in disease activity and fibrosis for patients with metabolic dysfunction-associated steatohepatitis.
| 6 min read
A liver enzyme affects fibrosis progression by altering metabolism of the sugar trehalose in the gut.
| 3 min read
As an alternative to daily pills, a new RNAi drug could lower blood pressure with a twice-yearly injection.
| 7 min read
With a high mortality rate and no treatment, alcoholic hepatitis is a tragic diagnosis. But a new molecule that alters patient epigenetics may become the first effective therapy for the disease.
| 3 min read
Scientists found that the Kisspeptin hormone activates enzymes that stop lipid formation in the mouse liver, suggesting that it has potential as a drug target for treating non-alcoholic fatty liver disease.
| 10+ min read
Through academic, industry, and governmental partnerships, scientists validate and develop non-invasive diagnostics for non-alcoholic fatty liver disease. These tests are set to replace the invasive and risky gold standard: liver biopsy.
Page 1 of 1 - 6 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Reliable fluid biomarkers strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Understanding drug impurities: types, sources, and analytical strategies
Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Discovering cutting-edge nitrosamine analysis in pharmaceuticals
New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
